Siteman Kids is the First Site of Multicenter CAR-T Trial for Autoimmune Diseases

Access to the novel immunotherapy — which “has the potential for cure” — is the latest offering by the national leader in pediatric hematology, oncology, and cell therapies. Siteman Kids at St. Louis Children’s Hospital, along with WashU Medicine in St. Louis, is the first site to test a novel immunotherapy drug for the […]
Promising Memory-Like NK Cell Therapy Spurs Trial Expansion Available Only at Siteman Kids at St. Louis Children’s Hospital and Siteman Cancer Center

ST. LOUIS — Oncologists at WashU Medicine in St. Louis are expanding an ongoing stem cell transplant study that previously enrolled only patients in remission. The study — shown to be safe and effective and aimed at preventing relapse — now also includes patients with refractory disease and those with two or more transplants. […]
More Than 30 Countries Now Participate in Siteman Kids’ Pediatric Neuro-Oncology Tumor Boards

Collaborative Approach Enhances Care for Children with Brain Tumors and NF Worldwide An international pediatric brain tumor board established by Mohamed Shebl Abdelbaki, MD, WashU Medicine pediatric oncologist and director of the Pediatric Neuro-Oncology Program at Siteman Kids at St. Louis Children’s Hospital, is rapidly becoming a collaborative, global force in efforts to better […]
Enrolling Now: ‘High Five’ Study Investigates Short-Term, High-Dose Radiation Therapy for High-Risk Prostate Cancer

A promising study evaluating the use of ultra-hypofractionation radiation therapy for the treatment of high-risk prostate cancer is underway at all six locations of Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. Called the “High Five” clinical trial, or NRG-GU-013, the phase III multicenter study will help determine whether five high-dose stereotactic body […]
Immunotherapy improves survival of patients with locally advanced head and neck cancer

Approved drug that revolutionized melanoma treatment may change standard of care for yet another cancer type Research presented at the annual meeting of the American Association for Cancer Research (AACR) in April provides the strongest clinical evidence to date that standard of care therapy could soon be updated for the treatment of resectable locally advanced […]
New Phase 2 Clinical Trial Opens for Rare Leukemia/Lymphoma in Children

Off-the-shelf cellular therapy targets relapsed or refractory T-cell leukemia/lymphoma A potentially groundbreaking clinical trial is now open at Siteman Kids at St. Louis Children’s Hospital to evaluate an allogeneic, off-the-shelf cellular therapy designed to treat patients with relapsed or refractory T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/LBL). Siteman Kids is one of […]
Vaccine Shows Promise Against Aggressive Breast Cancer

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, the trial is the first to report results for this type of vaccine — known as […]
New Clinical Trial Focused on Relapse Prevention in Patients with Acute Myeloid Leukemia Undergoing Bone Marrow Transplant

Investigator-Initiated Trial; Only Available at Siteman Cancer Center, Siteman Kids in St. Louis ST. LOUIS — A new and promising clinical trial aimed at preventing relapse in patients diagnosed with acute myeloid leukemia (AML) is now open at Washington University School of Medicine in St. Louis. The trial (NCT06158828) is only available to […]
New Clinical Trials Open for Sarcomas and Solid Tumors

Two exciting early phase clinical trials are underway at Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, that leverage novel classes of drugs and exploit how proteins can be targeted and/or removed to stop uncontrolled cell division that occurs in sarcomas and solid tumors. For BRAF B600 […]
Whole Genome Sequencing for AML/MDS Risk Stratification

ChromoSeq now covered by Medicare; Two Clinical Trials Also Open Two novel clinical trials for patients diagnosed with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) are open and enrolling patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. The clinical trials are utilizing a breakthrough whole-genome […]